Clinical Trial Update: Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of bevacizumab plus irinotecan for patients with primary brain tumors has completed enrollment and status is updated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Glioma

Drugs mentioned

• Avastin (bevacizumab)
• Camptosar (irinotecan)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Brain Neoplasms, Glioma | Phase 2 | Status: COMPLETED